To investigate the neuroprotective potential of SGLT2 inhibition against AD pathology, we administered Enavogliflozin, a potent SGLT2 inhibitor, to 5XFAD mice beginning at 5 months of age. The gene discussed is SLC5A2; the disease is Alzheimer disease.